scholarly journals Application of Concomitant Disease Scoring in Acute Cerebral Infarction

2020 ◽  
Vol 22 (3) ◽  
Author(s):  
Xiao-Jing Zhao ◽  
Qun-Xi Li ◽  
Ying Liu ◽  
Li-Sha Chang ◽  
Rui-Ying Chen ◽  
...  
Keyword(s):  
Cerebral Infarction ◽  
Acute Cerebral Infarction ◽  
Concomitant Disease ◽  
Disease Scoring

scholarly journals Application of concomitant disease scoring in acute cerebral infarction

2019 ◽  
Author(s):  
Xiao-Jing Zhao ◽  
Qun-Xi Li ◽  
Ying Liu ◽  
Li-Sha Chang ◽  
Rui-Ying Chen ◽  
...  
Keyword(s):  
Cerebral Infarction ◽  
Predictive Value ◽  
Goodness Of Fit ◽  
Operating Characteristic ◽  
Acute Cerebral Infarction ◽  
Concomitant Disease ◽  
Disease Score ◽  
Goodness Of Fit Test ◽  
Ideal System ◽  
Disease Scoring

Abstract Background: This study aims to explore the predictive value of concomitant disease scoring for the prognosis of patients with acute cerebral infarction (ACI). Methods: A total of 399 patients with ACI, who met the inclusion criteria, were enrolled into the present study. The concomitant disease score was assessed within 24 hours after admission, and the risk degree of death was analyzed. Then, the goodness of fit test and validity analysis were carried out, the best survival/death cut-off value was determined, and its predictive value for the prognosis of ACI patients was assessed. Results: The area under the receiver operating characteristic (ROC) curve for the concomitant disease score was 0.700, the distinctiveness was relatively good, and the prediction cut-off value was 10 points. Furthermore, the mortality rate of patients with a higher score was significantly higher, when compared to patients with a lower score. Conclusion: This concomitant disease score has good predictive value for the prognosis of ACI patients, and is an ideal system for evaluating the condition of cerebral infarction. The survival/death cut-off value was 10 points.

scholarly journals Long-Term Safety and Efficacy of Antiplatelet Therapy in Patients With Cerebral Infarction With Thrombocytopenia

2021 ◽  
Vol 27 ◽  
pp. 107602962098006
Author(s):  
Shijie Guo ◽  
Yingying Lin ◽  
Xiaoye Ma ◽  
Yanxin Zhao ◽  
Aiping Jin ◽  
...  
Keyword(s):  
Cerebral Infarction ◽  
Antiplatelet Therapy ◽  
Multivariate Regression Analysis ◽  
Acute Cerebral Infarction ◽  
Score Change ◽  
Recurrence Rates ◽  
Primary Endpoints ◽  
Hemorrhagic Events

This study aimed to investigate the long-term safety and benefits of antiplatelet therapy in patients with cerebral infarction with thrombocytopenia, as evidence regarding this was limited. This cohort trial assessed patients with acute cerebral infarction with thrombocytopenia treated in the Neurology Department of Shanghai Tenth People’s Hospital from January 2016 to December 2018, and enrolled patients were followed up for 9 months. The patients were divided into non-antiplatelet and antiplatelet groups based on the actual intake of antiplatelet drugs. Primary endpoints included hemorrhagic events, recurrence of cerebral infarction, and activity of daily living (ADL) score changes. To balance baseline clinical data, propensity score matching was applied, and there were finally 65 matched patients, including 30 and 35 in the antiplatelet and non-antiplatelet groups, respectively. There were no differences in hemorrhagic and cerebral infarction recurrence rates between the 2 groups. ADL score change was higher in the antiplatelet group than in the non-antiplatelet group (10 vs 5, p = 0.039). In multivariate regression analysis, antiplatelet therapy significantly predicted a positive change in ADL scores [B = 8.381, 95% confidence interval (0.56-16.19)]. In patients with acute cerebral infarction with thrombocytopenia, antiplatelet therapy could the improve the quality of life in the chronic stage.

Sign in / Sign up

Export Citation Format

Share Document